X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1090) 1090
Patent (50) 50
Book Chapter (9) 9
Book / eBook (4) 4
Web Resource (3) 3
Conference Proceeding (1) 1
Magazine Article (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (517) 517
melanoma (393) 393
oncology (324) 324
male (248) 248
female (245) 245
middle aged (206) 206
cancer (190) 190
aged (174) 174
adult (169) 169
melanoma - drug therapy (157) 157
melanoma - pathology (157) 157
melanoma - genetics (143) 143
metastasis (127) 127
dermatology (124) 124
immunotherapy (122) 122
skin neoplasms - pathology (113) 113
survival (103) 103
mutation (102) 102
skin neoplasms - drug therapy (102) 102
aged, 80 and over (98) 98
skin cancer (90) 90
ipilimumab (87) 87
melanoma - mortality (84) 84
metastatic melanoma (84) 84
tumors (83) 83
metastases (80) 80
prognosis (80) 80
skin neoplasms - genetics (78) 78
care and treatment (75) 75
patients (72) 72
treatment outcome (71) 71
cell biology (70) 70
analysis (69) 69
melanoma - immunology (69) 69
malignant-melanoma (67) 67
melanoma - metabolism (67) 67
melanoma - secondary (67) 67
biochemistry (66) 66
expression (65) 65
chemotherapy (64) 64
melanoma - therapy (64) 64
antineoplastic agents - therapeutic use (63) 63
young adult (61) 61
animals (60) 60
immunology (60) 60
proto-oncogene proteins b-raf - genetics (60) 60
cell line, tumor (58) 58
therapy (57) 57
neoplasm staging (56) 56
adolescent (54) 54
skin neoplasms - mortality (53) 53
clinical trials (52) 52
research (50) 50
microbiology (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
chemistry (47) 47
peptides (47) 47
beer (46) 46
cutaneous melanoma (46) 46
enzymology (46) 46
metallurgy (46) 46
mutation or genetic engineering (46) 46
spirits (46) 46
vinegar (46) 46
wine (46) 46
gene expression regulation, neoplastic (45) 45
human necessities (45) 45
hygiene (45) 45
medical or veterinary science (45) 45
kaplan-meier estimate (44) 44
nivolumab (44) 44
disease-free survival (43) 43
risk factors (43) 43
skin (43) 43
preparations for medical, dental, or toilet purposes (42) 42
disease progression (41) 41
hematology, oncology and palliative medicine (41) 41
mice (40) 40
vemurafenib (40) 40
tumor cells, cultured (38) 38
compositions thereof (37) 37
culture media (37) 37
medical research (37) 37
melanoma - diagnosis (37) 37
microorganisms or enzymes (37) 37
propagating, preserving or maintaining microorganisms (37) 37
organic chemistry (36) 36
skin neoplasms - therapy (36) 36
time factors (36) 36
610 medicine & health (35) 35
braf (35) 35
genetic aspects (35) 35
mutations (35) 35
survival analysis (35) 35
abridged index medicus (34) 34
lymphocytes (33) 33
malignant melanoma (33) 33
medicine, research & experimental (33) 33
proto-oncogene proteins b-raf - antagonists & inhibitors (33) 33
dabrafenib (32) 32
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1086) 1086
German (97) 97
French (24) 24
Spanish (2) 2
Danish (1) 1
Hungarian (1) 1
Polish (1) 1
Portuguese (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 323 - 332
Summary Background In the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with... 
Hematology, Oncology and Palliative Medicine
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article